nach oben

Drugs

Erschienen in:

01.06.2004 | Correspondence

The Authors’ Reply

verfasst von: James D. Douketis, Arya M. Sharma

Erschienen in: Drugs | Ausgabe 11/2004

Einloggen, um Zugang zu erhalten

Excerpt

We thank Dr Jacob for his letter and agree that additional commentary is warranted to explain our statement that orlisat has “…inconsistent effects on blood pressure and may benefit only patients who have uncontrolled or non-medicated hypertension”. Furthermore, we appreciate the relevant information provided by Dr Jacob from the XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study, which assessed normotensive and hypertensive obese patients but was not included in our review as it was just recently published.[1] …

Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–61PubMedCrossRef

Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 1998; 352: 167–72PubMedCrossRef

Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42PubMedCrossRef

Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245–54PubMedCrossRef

Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res 2000; 8: 49–61PubMedCrossRef

Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160–7PubMedCrossRef

Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306–13PubMedCrossRef

Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288–94PubMedCrossRef

Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25: 1033–41PubMedCrossRef

10.

Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002; 25: 1123–8PubMedCrossRef

11.

Broom I, Wilding J, Stott P, et al. Randomised trial of the effects of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int J Clin Pract 2002; 56: 494–9PubMed

12.

Bakris G, Calhoun D, Hellman C, et al., on behalf of the Orlistat and Resistant Hypertension Investigators. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002; 20: 2257–67PubMedCrossRef

13.

Douketis JD, Sharma AM. The management of hypertension in the overweight and obese patient: is weight reduction sufficient? Drugs 2004; 64(8): 795–803PubMedCrossRef

14.

Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52PubMedCrossRef

15.

Khan NA, McAlister FA, Campbell NR, et al. The 2004 Canadian recommendations for the management of hypertension. Part II: therapy. Can J Cardiol 2004; 20: 41–54

Titel: The Authors’ Reply
verfasst von: James D. Douketis
Arya M. Sharma
Publikationsdatum: 01.06.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 11/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464110-00008

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2004

Evolving Strategies for Insulin Delivery and Therapy

Valdecoxib

The Management of Hypertension in the Overweight and Obese Patient

Mucosal and Systemic Fungal Infections in Patients with AIDS

Zoledronic Acid

Letrozole